ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM

AZD1775 is an oral small molecular inhibitor of the G2/M checkpoint regulator Wee1. The Adult Brain Tumor Consortium 1202 trial (NCT01849146) is a phase I, open label, multicenter dose-finding study of AZD1775 in combination with standard RT and TMZ followed by an IDD study for patients undergoing s...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Neuro Oncol
Κύριοι συγγραφείς: Alexander, Brian, Supko, Jeffrey, Agar, Nathalie, Ahluwalia, Manmeet, Desai, Arati, Dietrich, Jorg, Kaley, Thomas, Peereboom, David, Takebe, Naoko, Desideri, Serena, Fisher, Joy, Sims, Megan, Ye, Xiaobu, Ligon, Keith, Nabors, L Burt, Grossman, Stuart, Wen, Patrick
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Oxford University Press 2018
Θέματα:
Abstracts
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216169/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.048
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια